先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

已收盘 05-11 16:08:03

11.780

-0.180

-1.51%

最高11.970	最低11.670	成交量596.50万
今开11.950	昨收11.960	日振幅2.51%
总市值305.81亿	流通市值305.81亿	总股本25.96亿
成交额7,043万	换手率0.23%	流通股本25.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":11.78,"timestamp":1778486883004,"preClose":11.96,"halted":0,"volume":5965000,"delay":0,"changeRate":-0.015050167224080391,"floatShares":2596000000,"shares":2596000000,"eps":0.6223856342173655,"marketStatus":"已收盘","change":-0.18,"latestTime":"05-11 16:08:03","open":11.95,"high":11.97,"low":11.67,"amount":70430182,"amplitude":0.025084,"askPrice":11.79,"askSize":7000,"bidPrice":11.78,"bidSize":38000,"shortable":3,"etf":0,"ttmEps":0.6223856342173655,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778549400000},"marketStatusCode":5,"adr":0,"listingDate":1603728000000,"exchange":"SEHK","adjPreClose":11.96,"dividendRate":0.017308,"openAndCloseTimeList":[[1778463000000,1778472000000],[1778475600000,1778486400000]],"volumeRatio":1.440983,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096","defaultTab":"news","newsList":[{"id":"1143488988","title":"先声药业更新2026年4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1143488988","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143488988?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:38","pubTimestamp":1778056738,"startTime":"0","endTime":"0","summary":"2026年5月6日，先声药业披露2026年4月的股份变动月报表，截至2026年4月30日，公司普通股已发行股份总数为2,595,697,618股，与上月底持平，库存股份为0股，显示报告期内并无新增发行或实际注销股份。此外，先声药业于2025年6月13日回购12,825,000股股份，相关股份目前处于拟注销但尚未注销状态。截至2026年4月底，当月并无任何因该受限制股份单位计划所新增的已发行股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633739889","title":"先声药业(02096)：SIM0613(LRRC15抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2633739889","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633739889?lang=zh_cn&edition=full","pubTime":"2026-05-06 07:03","pubTimestamp":1778022236,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业 发布公告，本集团自主研发的靶向LRRC15的抗体偶联药物注射用SIM0613已获得中国国家药品监督管理局签发的药物临床试验批准通知书，拟开展晚期实体瘤的临床试验。LRRC15在多种实体瘤和肿瘤相关成纤维细胞表面高表达，但正常细胞中极少表达。SIM0613与LRRC15蛋白结合后通过内吞进入肿瘤细胞后，释放细胞毒性有效载荷，从而杀死肿瘤细胞，同时较少影响正常细胞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业(02096)：SIM0613(LRRC15抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165416402","title":"先声药业SIM0613获国家药监局临床试验批准 用于晚期实体瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165416402","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165416402?lang=zh_cn&edition=full","pubTime":"2026-05-06 07:02","pubTimestamp":1778022135,"startTime":"0","endTime":"0","summary":"先声药业宣布，其创新药物SIM0613已获得中国国家药品监督管理局（NMPA）颁发的临床试验批件，该药物将用于晚期实体瘤患者的临床治疗研究。\n此次获批标志着先声药业在肿瘤创新药研发领域取得重要进展。SIM0613作为公司自主研发的抗肿瘤新药，其临床试验的启动将为晚期实体瘤患者提供新的治疗选择。\n公司表示将严格按照法规要求推进临床试验工作，并持续关注肿瘤治疗领域的未满足临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633191134","title":"先声药业(02096)5月5日斥资1619.3万港元回购137.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633191134","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633191134?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:37","pubTimestamp":1777977422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年5月5日斥资1619.3万港元回购137.9万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260505/32200936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168179465","title":"先声药业回购137.9万股，耗资约1619.28万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168179465","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168179465?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:32","pubTimestamp":1777977137,"startTime":"0","endTime":"0","summary":"2026年5月5日，先声药业集团有限公司公告称，于当日于香港联交所场内回购股份，共计回购1,379,000股普通股，约占公司已发行股本的0.0531%。本次回购价格介乎每股港币11.6至11.8033元，总计付出约港币1619.28万元。公告显示，截至2026年5月5日，公司已发行股本仍为2,595,697,618股，库藏股数量为0股。本次回购基于公司于2025年6月13日通过的购回授权，该授权允许公司回购的最高股份总数为247,469,761股。公司在公告中表示，已遵守香港联合交易所证券上市规则以及相关法律的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业回购137.9万股，耗资约1619.28万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126333829","title":"先声药业5月4日回购84.7万股，耗资约1,001.65万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126333829","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126333829?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:37","pubTimestamp":1777891065,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年5月4日发布公告，披露该公司在香港联交所场内回购股份。公告显示，先声药业于当日回购84.7万股普通股，占事件前已发行股本约0.0326%，每股回购价介乎港币11.65港元至11.91港元，合计动用资金约10,016,537.3港元。先声药业公告披露，此次回购股份尚未被注销，公司已发行股本仍为2,595,697,618股，库存股数为0。公告中同时确认，相关回购行为符合香港联交所上市规则与所有适用法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业5月4日回购84.7万股，耗资约1,001.65万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632329099","title":"先声药业(02096)5月4日斥资1001.65万港元回购84.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2632329099","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632329099?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:36","pubTimestamp":1777890988,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年5月4日斥资1001.65万港元回购84.7万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437892.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631689880","title":"先声药业(02096)：乐德奇拜单抗新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2631689880","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631689880?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:50","pubTimestamp":1777539057,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业 发布公告，于2026年4月29日，集团重新提交的与香港康乃德生物医药有限公司合作的创新药乐德奇拜单抗新药上市申请获国家药品监督管理局受理，用于治疗成人及青少年特应性皮炎。乐德奇拜单抗与IL-4Rα结合可以有效阻断IL-4和IL-13功能，进而阻断 Th2型炎症通路，从而达到有效治疗特应性皮炎及哮喘等Th2相关炎症性疾病的目的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175808389","title":"先声药业(02096)2025年营收达77.31亿元 创新药贡献率81.5% 净利润同比大增86.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175808389","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175808389?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:39","pubTimestamp":1777376383,"startTime":"0","endTime":"0","summary":"财务数据显示，截至2025年12月31日止年度，公司实现营业收入人民币77.31亿元，同比2024年的人民币66.35亿元上升16.5%。其中创新药业务收入达人民币63.04亿元，占整体收入的81.5%，同比增长27.9%。报告期内归属于公司权益股东的净利润为人民币13.44亿元，较上一年度的人民币7.22亿元增长86.2%；经调整净利润为人民币12.80亿元，同比增长27.1%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业(02096)2025年营收达77.31亿元 创新药贡献率81.5% 净利润同比大增86.2%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629408028","title":"先声药业(02096)：已主动撤回乐德奇拜单抗的NDA，并预计本月重新递交NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2629408028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629408028?lang=zh_cn&edition=full","pubTime":"2026-04-22 23:01","pubTimestamp":1776870112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业 发布公告，本集团与香港康乃德生物医药有限公司合作的创新药乐德奇拜单抗新药上市申请获国家药品监督管理局受理，用于治疗成人及青少年特应性皮炎。出于产品整体商业化布局的战略优化，本公司已主动撤回乐德奇拜单抗的NDA，并预计本月重新递交NDA。叁期临床研究显示，乐德奇拜单抗不仅起效迅速，且在持续治疗后的累积获益更为显著，呈现与同类产品相比更有效的潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123017418","title":"先声药业撤回雷德奇单抗上市申请 计划2026年4月前重新提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1123017418","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123017418?lang=zh_cn&edition=full","pubTime":"2026-04-22 22:47","pubTimestamp":1776869235,"startTime":"0","endTime":"0","summary":"先声药业宣布主动撤回雷德奇单抗（Rademikibart）的新药上市申请。公司表示，此次撤回是基于与监管机构沟通后的策略调整，计划在2026年4月前完成数据补充并重新提交申请。\n该药物针对特应性皮炎等自身免疫疾病研发，此次技术性撤回不影响其核心临床进展。企业强调将加速推进后续工作，力争按既定时间表实现产品上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176812093","title":"先声药业更新2026年3月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1176812093","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176812093?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:47","pubTimestamp":1775119675,"startTime":"0","endTime":"0","summary":"先声药业于2026年4月2日发布2026年3月股份变动月报表，报告期为2026年3月1日至3月31日。公告显示，截至3月31日，公司已发行股份总数为2,595,697,618股，与上月底保持一致，库藏股份数量仍为0股，注册股本无变动。公告还提及公司此前于2025年6月13日回购了12,825,000股股份，惟该批股份仍处于“拟注销”状态，截至3月31日尚未实际注销，故报告期内已发行股份总数最终未发生变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623390139","title":"交银国际：升先声药业(02096)目标价至17.7港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2623390139","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623390139?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:34","pubTimestamp":1774859659,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，将先声药业目标价上调至17.7港元，维持“买入”评级及行业重点推荐。公司2025年收入和经调整净利润分别同比增长16.5%和27.1%，分别达77.3亿和12.8亿元人民币，剔除授权许可收入后的产品收入增速为9.5%。管理层预计，2026年将有IL-4R和流感药两款新品获批上市、叠加与BI的合作4,200万欧元首付款确认收入，驱动收入和经调整净利润达到100亿和16亿元人民币左右，对应约30%的增速。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","BK1161","IE00B5MMRT66.SGD","LU2148510915.USD","09926","LU0348767384.USD","LU0561508036.HKD","LU2778985437.USD","09995","IE00BPRC5H50.USD","LU0348766576.USD","00013","00512","LU0417516571.SGD","LU0634319403.HKD","IE00B543WZ88.USD","LU2399975544.HKD","LU0417516902.SGD","BK1583","LU0348783233.USD","LU1064130708.USD","LU2328871848.SGD","LU0348735423.USD","LU2488822045.USD","LU1720050803.USD","BK1588","LU1064131003.USD","LU1969619763.USD","02096","159992","LU0348827113.USD","LU1794554557.SGD","LU2476274308.USD","LU1961090484.USD","LU2476274720.SGD","BK1191","LU0417516738.SGD","688331","BK1587","09969","BK1574","06978","BK0239","LU0540923850.HKD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622257448","title":"恒瑞老将正式执掌先声药业 昔日内幕交易引合规评估","url":"https://stock-news.laohu8.com/highlight/detail?id=2622257448","media":"经济参考网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622257448?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:42","pubTimestamp":1774611748,"startTime":"0","endTime":"0","summary":"从2025年12月首次以总裁身份出现在江苏省肿瘤医院与先声药业（02096.HK）的战略合作签约仪式，到如今正式执掌一家百亿市值的上市创新药企，近期周云曙接任先声药业CEO引发市场关注。3月25日，先声药业在公布2025年财报的同时官宣了一项人事任命，宣布周云曙获委任为公司首席执行官。在业绩发布会上，周云曙表示，先声药业2026年的经营目标是营业收入突破100亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273687234875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814803","title":"港股异动 | 先声药业(02096)午前涨近8% 恒瑞医药前董事长周云曙正式出任先声药业CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814803","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814803?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:01","pubTimestamp":1774584119,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业午前涨近8%，截至发稿，涨7.87%，报12.06港元，成交额4559.2万港元。消息面上，3月25日，先声药业公告披露，恒瑞医药原董事长周云曙正式加盟，获聘首席执行官。先声药业近日发布的年度业绩显示。目前，先声药业已拥有10款上市创新药，还有超5款临近上市创新药，预计于2026-2028年获批，蓄力未来持续增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU2580892789.USD","LU1255011170.USD","LU0405327494.USD","LU1328615791.USD","LU2289578879.USD","600276","VXUS","BK4588","LU0359201612.USD","BK0183","LU1781817850.SGD","BK0188","LU1655091616.SGD","LU2488822045.USD","LU2328871848.SGD","LU2097828714.EUR","LU1580142542.USD","01276","LU0359202008.SGD","02096","LU2495084118.USD","LU1820825898.SGD","BK0012","LU1969619763.USD","LU1146622755.USD","LU1064130708.USD","LU2097828474.EUR","BK4585","LU0405327148.USD","LU2097828805.USD","BK0060","LU2580892862.HKD","LU2097828631.EUR","LU2097828557.USD","BK0196","BK1191","LU1997244956.HKD","LU1023057109.AUD","LU1064131003.USD","LU1997245177.USD","LU1997245094.SGD","BK0239","LU2148510915.USD","LU2543165471.USD","LU0359201885.HKD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111219149","title":"异动解读 | 业绩超预期叠加新CEO公布百亿目标，先声药业盘中大涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111219149","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111219149?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:02","pubTimestamp":1774576968,"startTime":"0","endTime":"0","summary":"先声药业今日盘中股价大幅上涨5.46%，市场表现活跃。消息面上，公司于前一晚发布了2025年度业绩报告，显示其总收入达77.31亿元，同比增长16.5%；归母净利润为13.44亿元，同比大幅增长86.2%。与此同时，公司宣布了重要人事变动，由拥有近三十年行业经验的资深人士周云曙接任首席执行官。在随后的业绩会上，新任CEO周云曙公布了公司2026年的“双30”目标：营业收入挑战100亿元，经调整净利润同比增长30%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622289783","title":"信达生物2025年首次扭亏为盈；周云曙出任先声药业CEO | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2622289783","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622289783?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:00","pubTimestamp":1774566006,"startTime":"0","endTime":"0","summary":"丨2026年3月27日星期五丨NO.1京东健康宿迁天宁股权结构调整3月26日，京东健康宣布，为提高行政效率，李娅云于2026年3月26日订立股权转让协议，据此李娅云同意将其在宿迁天宁持有的30%股权转让予隋婷婷。由于一名登记股东变更，宿迁天宁、外商独资企业及新登记股东订立新合同安排，现有合同安排同时终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686096042.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686096042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997244956.HKD","LU2580892789.USD","BK1161","HK0000165453.HKD","LU0405327494.USD","LU2495084118.USD","LU2328871848.SGD","BK1574","BK0239","LU1064130708.USD","BK1583","LU1655091616.SGD","01801","LU2242644610.SGD","600276","LU1820825898.SGD","LU2097828631.EUR","LU2097828714.EUR","LU1781817850.SGD","LU2148510915.USD","LU2097828805.USD","BK0183","BK0060","02096","BK1589","LU0502904849.HKD","LU1328615791.USD","BK0028","09939","BK0012","LU1255011170.USD","159938","LU2289578879.USD","LU1997245177.USD","LU1997245094.SGD","BK1191","LU2097828474.EUR","LU2097828557.USD","LU0455707207.USD","LU2580892862.HKD","LU0405327148.USD","BK0196","BK0188","LU1146622755.USD","LU1580142542.USD","BK1515","LU1064131003.USD","LU2488822045.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622731850","title":"先声药业(02096.HK)：授出合共216.9万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2622731850","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622731850?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:47","pubTimestamp":1774529225,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨先声药业(02096.HK)布，于2026年3月26日，其议决根据2021年受限制股份单位计划按零代价向合共54名合资格参与者授出合共216.9万份受限制股份单位(相当于216.9万股相关股份)，惟须待承授人接纳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32102134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172271995","title":"先声药业：3月26日回购197.40万股，耗资约2,203.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172271995","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172271995?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:06","pubTimestamp":1774526800,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年3月26日公告，披露该公司在香港联交所场内回购股份。根据公告，公司本次回购股份数量为1,974,000股，占已发行股本约0.076%。每股回购价介乎港币10.9444元至11.3272元，合计耗资约22,032,406港元。公司此前于2025年6月13日获得购回授权，授权可购回的总数为247,469,761股；截至目前，已根据购回授权回购12,825,000股，占授权决议通过当日公司已发行股本约0.5182%。公告同时指出，公司确认已遵守香港联交所证券上市规则及其他相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":0.0101},{"period":"1month","weight":-0.1289},{"period":"3month","weight":-0.014},{"period":"6month","weight":-0.0324},{"period":"1year","weight":0.3943},{"period":"ytd","weight":-0.0008}],"compareEarnings":[{"period":"1week","weight":0.0239},{"period":"1month","weight":0.0193},{"period":"3month","weight":-0.0063},{"period":"6month","weight":0.0058},{"period":"1year","weight":0.1588},{"period":"ytd","weight":0.0298}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药，包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药，比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.093182},{"month":2,"riseRate":0.666667,"avgChangeRate":0.070781},{"month":3,"riseRate":0.5,"avgChangeRate":-0.014071},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003689},{"month":5,"riseRate":0.833333,"avgChangeRate":0.133975},{"month":6,"riseRate":0.6,"avgChangeRate":0.036684},{"month":7,"riseRate":0.2,"avgChangeRate":-0.0521},{"month":8,"riseRate":0.4,"avgChangeRate":-0.05132},{"month":9,"riseRate":0.4,"avgChangeRate":-0.0324},{"month":10,"riseRate":0.8,"avgChangeRate":0.108781},{"month":11,"riseRate":0.666667,"avgChangeRate":0.044275},{"month":12,"riseRate":0.5,"avgChangeRate":0.000552}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}